Welcome to our dedicated page for JNCE news (Ticker: JNCE), a resource for investors and traders seeking the latest updates and insights on JNCE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JNCE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JNCE's position in the market.
Jounce Therapeutics (NASDAQ: JNCE) will disclose its first quarter 2022 financial results and provide a corporate update on May 5, 2022. A live conference call, accessible via telephone and webcast, is scheduled for 8:00 a.m. ET. The company is focused on developing novel cancer immunotherapies, with ongoing clinical trials for key product candidates like JTX-8064 and vopratelimab. Jounce aims to transform cancer treatment through a biomarker-driven approach, leveraging its Translational Science Platform to advance multiple development-stage programs.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) announced participation in a fireside chat at the Raymond James LILRB/ILT Symposium on April 26, 2022, at 1:00 pm ET. The symposium will focus on 'Myeloid Checkpoint' therapeutics in cancer. Jounce is dedicated to developing innovative cancer immunotherapies through a biomarker-driven approach. Its lead program, JTX-8064, targets immune-suppressive tumor-associated macrophages, while other candidates like vopratelimab and pimivalimab are in various stages of clinical trials. For more information, visit www.jouncetx.com.
Jounce Therapeutics (NASDAQ: JNCE) reported its 2021 financial results, highlighting a cash position of $220.2 million as of December 31, 2021. The company is progressing on two clinical trials, INNATE and SELECT, with important data expected in 2022. Revenue recognition decreased to $26.9 million for 2021, down from $62.3 million in 2020, primarily due to reduced collaboration revenue. Net loss for Q4 was $30.2 million, leading to a full-year net loss of $90.9 million. Jounce anticipates a gross cash burn of $115-$130 million for 2022, with sufficient funds to cover expenses into Q3 2023.
Jounce Therapeutics (NASDAQ: JNCE) announced its participation in a novel immuno-oncology panel at the Cowen & Co. 42nd Annual Health Care Conference on March 7, 2022, at 10:30 a.m. ET. The session will be accessible via webcast on Jounce's website, with a replay available for 30 days post-event. Jounce is focused on developing cancer immunotherapies and currently advancing programs like JTX-8064, a receptor antagonist targeting immune-suppressive tumor macrophages, and vopratelimab, an ICOS-activating monoclonal antibody.
Jounce Therapeutics (NASDAQ: JNCE) will announce its fourth quarter and full year 2021 financial results on March 2, 2022, before market open. The live conference call will start at 8:00 a.m. ET, allowing investors to gain insights into the company's performance and upcoming developments. Jounce is focused on cancer immunotherapy and has ongoing clinical trials, including the Phase 1/2 INNATE trial for JTX-8064, its lead program. It also has licensed GS-1811 to Gilead Sciences, enhancing its strategic partnerships.
Jounce Therapeutics (NASDAQ: JNCE) has announced its participation in two investor conferences in January 2022. The H.C. Wainwright BioConnect Virtual Conference will feature a presentation available on-demand from January 10, 2022, at 7:00 a.m. ET. The 40th Annual J.P. Morgan Healthcare Conference will include a live presentation on January 13, 2022, at 12:00 p.m. ET. Webcasts of both presentations can be accessed via Jounce’s website for 30 days post-event.
Jounce focuses on developing cancer immunotherapies and predictive biomarkers, with key programs including JTX-8064 and vopratelimab in various clinical trials.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) announced participation in two investor conferences in November 2021. The 5th Annual Cowen IO Next Summit will feature a fireside chat on November 15 at 10:45 a.m. ET, while the 33rd Annual Piper Sandler Healthcare Conference will offer on-demand viewing starting November 22 at 10:00 a.m. ET. Webcasts can be accessed on Jounce's website, with replays available for 30 days. Jounce is focused on developing cancer immunotherapies, including their candidate JTX-8064 and vopratelimab, among others.
Jounce Therapeutics (NASDAQ: JNCE) reported progress in its clinical trials, particularly in the INNATE study of JTX-8064, with active patient recruitment in tumor-specific cohorts. As of September 30, 2021, the company held $249 million in cash and equivalents, up from $213.2 million at the end of 2020. The third quarter net loss was $30.1 million, but the loss per share improved to $0.59 due to an increased number of shares. Jounce projects a cash burn of $100-110 million for 2021 and expects to have around $220 million by year-end.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) will release its third quarter 2021 financial results on November 4, 2021, before the market opens. A live conference call and webcast will follow at 8:00 a.m. E.T. The company focuses on developing cancer immunotherapies and predictive biomarkers, with ongoing programs including JTX-8064 and vopratelimab. Jounce has also licensed GS-1811 to Gilead Sciences. This update is part of Jounce's commitment to transforming cancer treatment with a biomarker-driven approach.
Jounce Therapeutics initiated patient enrollment for tumor-specific expansion cohorts in the ongoing INNATE trial, focusing on JTX-8064 monotherapy and its combination with pimivalimab. Following the completion of dose escalations, this phase aims to address patients previously treated with PD-1 inhibitors and those who are naïve to immuno-oncology treatment. The trial could enroll up to 29 or 47 patients based on pre-specified criteria. Success in these cohorts could lead to rapid progression into registrational trials.
